Angiotensin II antagonists are effective for hypertension management and provide significant cardiovascular and renal protection in diabetic nephropathy with excellent tolerability.
Answers are grounded in this paper and cite their sources.
ARBs may support hypertension management across groups and renal protection in diabetic nephropathy; leaves open updated comparisons with newer agents.
Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago. During this period they were evaluated not only in terms of efficacy and safety but also in several large studies with clinical outcomes. They are efficacious in all clinical forms of hypertension and are effective also in all ethnic groups. Cardiovascular and renal protection in proteinuric diabetic nephropathy beyond blood pressure reduction was proved in major clinical studies: Losartan Intervention For Endpoint reduction in hypertension study (LIFE), Reduction of Endpoint in Non-Insulin dependent Diabetes Mellitus with the AII Antagonist Losartan (RENAAL) and Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT). Their blood pressure independent protective effect is also mentioned by the blockade of AT1 receptor. As a class AIIs have a tolerability profile similar to placebo.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: